SCHEMBL2581347

SCHEMBL2581347

Cc1c(Cl)nc(O)c([N+](=O)[O-])c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.39
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
GPR35 Q9HC97 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
MAPK1 P28482 1/20 0.33
GFER P55789 1/20 0.33
S100A4 P26447 1/20 0.32
MAPT P10636 3/20 0.32
DCTPP1 Q9H773 1/20 0.32
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572330 0.81 MAPT (0.35) POLBMEN1KMT2AGPR35TDP1
SCHEMBL9125919 0.76 MEN1 (0.37) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6698344 0.72 MAPT (0.48) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL18227006 0.71 TSHR (0.38) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL596867 0.71 TDP1 (0.38) POLBMEN1KMT2AGPR35TDP1
SCHEMBL8057951 0.71 MEN1 (0.35) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL16297625 0.71 KMT2A (0.35) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7953310 0.71 POLB (0.41) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL15957619 0.71 GPR35 (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19617579 0.70 GPR35 (0.35) POLBMEN1KMT2AGPR35MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987030-B1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LTD (GB) 2011-11-09 EP disclosed
US-7691877-B2 Pharmaceuticals PFIZER INC. (US) 2010-04-06 US disclosed
CN-101384593-A 3-deazapurine derivatives as tlr7 modulators PFIZER LTD (GB) 2009-03-11 CN disclosed
EP-1987030-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS Pfizer Limited (GB) 2008-11-05 EP disclosed
WO-2007093901-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LIMITED (GB) 2007-08-23 WO disclosed
US-20070197478-A1 NOVEL PHARMACEUTICALS PFIZER LIMITED 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197478-A1 NOVEL PHARMACEUTICALS TLR3, HAVCR2, TLR9 POLB 1986/4885GRIN2D 4342/4885GRIN3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.